Where does Cellix Bio Private Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cellix Bio Private Limited ranks #5,146 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cellix Bio Private Limited hold?

Cellix Bio Private Limited holds 67 US utility patents granted between 2015 and 2024, spanning 7 technology areas.

What is Cellix Bio Private Limited's Innovation Score?

Cellix Bio Private Limited has an Innovation Score of 36.1 out of 100 (top 47% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cellix Bio Private Limited focus on?

Cellix Bio Private Limited's top technology area is C07D (Heterocyclic Compounds) with 57 patents, ranking #134 of 3,165 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Cellix Bio Private Limited's patent grant rate increasing or decreasing?

Cellix Bio Private Limited's recent grant velocity is -63% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Cellix Bio Private Limited's patents?

Cellix Bio Private Limited's patents average 9.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cellix Bio Private Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cellix Bio Private Limited

USPTO PatentsView assignee record - 67 granted patents across 7 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cellix ranks #5,146 of 49,997 tracked US assignees by granted-patent volume, with 67 patents across 7 technology areas.

#5,146
of 49,997 US assignees by volume: Top 47%
by Innovation Score (36.1/100): 9.2
avg claims per patent: -63%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5146 · Foreign Corporation #5,146 · 67 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 67 grants
UPPER-Q #5,146/49,997
PHOTO-FINISH Aviatrix Systems
CPC-NARROW C07D · 7 areas
INNOV-THIN 36.1/100
CLAIMS-PAR 9.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -63% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Aviatrix Systems, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cellix’s 36.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 14.6 pts (40%) Velocity 6.7 pts (19%) Breadth 9.4 pts (26%) Claim depth 5.5 pts (15%)

Qualcomm Incorporated · highest

85
Cellix Bio Private · this assignee

36
Germans Boada · near

36
Kempharm · near

36
Sengled Optoelectron… · near

36
Voicebox · near

36
3D Lighting… · lowest

7

What this shows Cellix's Innovation Score is 36.1/100 (top 47% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cellix?

Each dot is one of Cellix’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cellix’s own 9.2 claims/patent is at or below the 13.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cellix vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cellix's grants concentrate

Cellix Bio Private Limited is a focused PatentsView assignee: 7 CPC subclasses with 85.1% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2016 (29 grants) versus a trough of 1 in 2024. By volume, Cellix sits between Aviatrix Systems, Inc. and EKO Development Ltd..

Cellix's three-year grant acceleration

Cellix Bio Private Limited shows 10 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Aviatrix Systems

67
Beken

67
Cambridge Mechatr…

67
Children's Nation…

67
Chang Chun Plasti…

67
China Medical Uni…

67
De' Longhi Applia…

67
EKO Development

67
Cellix Bio Private ◀

67

What this shows Cellix holds 67 patents at rank #5,147, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cellix

By rank, the assignees closest to #5,147 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Cellix's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cellix, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Cellix ranks #134 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (36 here).

Kempharm, Inc. 36 Sengled Optoelectronics Co., Ltd. 36 Voicebox Technologies Corporation 36 Germans Boada, S.A. 36

Similar claim depth

Nearest assignees by average claims per patent (9.2 here).

Aruze Gaming America, Inc. 9.2 avg Wuhan University 9.2 avg YKK Corporation 9.2 avg Lapis Semiconductor Co., Ltd. 9.2 avg

Cellix's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

36 Top 47% higher than 53% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cellix Bio Private Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	9.0%
2016	29	43.3%
2017	10	14.9%
2018	2	3.0%
2019	2	3.0%
2020	3	4.5%
2021	5	7.5%
2022	6	9.0%
2023	3	4.5%
2024	1	1.5%

Which technologies does Cellix Bio Private Limited patent most?

C07D - Heterocyclic Compounds 57

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 53

C07C - Acyclic OR Carbocyclic Compounds 38

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 35

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cellix Bio Private Limited's patent record in context - here's where to go next.

Cellix Bio Private Limited's lead technology class is C07D (Heterocyclic Compounds), 85.1% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #5,146 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cellix Bio Private Limited against Aviatrix Systems, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 36.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.